Quasar passes FDA inspection with no 483 findings

Quasar passes FDA inspection with no 483 findings

An FDA inspection was conducted at the Quasar manufacturing facility in Shenzhen, October 31  to November 3, 2016.

This is the second consecutive FDA inspection Quasar passed with ZERO findings (no 483). This result endorses Quasar’s commitment to being a world-class medical device manufacturer.

Consistent with Quasar’s legacy of maintaining high quality standards, we focus on quality throughout the facility, whether in employee training, process development, equipment validations and all phases to manufacturing.

Read More

Quasar Excited to Announce Expansion of Services to Partners in China

A groundbreaking Chinese government policy change in August 2019 by the National Medical Products Administration (NMPA) will now grant any CFDA registered Contract Manufacturer the opportunity to become a Product Registered Manufacturing Contractor in China. Quasar is positioned to expand its abilities to manufacture, obtain necessary cross regional licensing, and participate as a government approved fully licensed registrant.

Read more...